Efficacy of galantamine for Alzheimer's disease leads April coverage
Click Here to Manage Email Alerts
A study demonstrating that galantamine, a cholinesterase inhibitor, significantly reduced risk for severe dementia over a 5-year period among patients with Alzheimer’s led neurology coverage in April.
Another top story reported on how specific neurological problems can serve as predictors of adverse outcomes in patients with COVID-19.
Read these and more top Healio Neurology stories below.
Multi-year study shows galantamine slows progression of Alzheimer’s dementia
Cholinesterase inhibitors provided moderate but persistent benefits in patients with Alzheimer’s dementia, including a lower risk for death, according to data published in Neurology. Read more.
Neurological symptoms with COVID-19 serve as ‘important predictor’ of poor outcomes
Patients with COVID-19 and certain neurological problems had longer hospital lengths of stay and higher in-hospital mortality, among other adverse outcomes, according to findings from a prospective cohort study of 211 hospitalized patients. Read more.
FDA orders more research into arrhythmia risk with Lamictal, other antiseizure drugs
The FDA ordered additional studies for Lamictal following a review of current research by the agency that demonstrated the potential for an increased risk for arrhythmias in patients with heart disease who are taking Lamictal. Read more.
Q&A: Functional neurological disorder is real, but not caused by ‘toxic vaccine effects’
Effective communication about the potential link between functional neurological disorder and COVID-19 vaccines “is critically important” to help inform the public and dimmish fears, according to a viewpoint published in JAMA Neurology. Read more.
Half of kids with MIS-C experience neurological symptoms
Preliminary research suggested half of children at a London hospital who developed a multisystem inflammatory syndrome associated with COVID-19 experienced neurological symptoms, such as headache, encephalopathy and hallucinations. Read more.
Follow us on Twitter @HealioNeurology to stay up to date on all the latest news in the field.